FABP5 and metabolic dysfunction-associated steatotic liver disease: Moreover, targeting hepatic asprosin gene inhibition and GalNAc‐siRNAs to inhibit hepatic FABP5 both offer potential therapeutic benefits in the treatment of MASLD.